首页 > 市场调查报告书 > 医疗设备

药物递输设备 DDS

市场调查报告书

商品编码

1623459

全球鼻腔给药技术市场规模（按产品类型、容器、应用、最终用户、区域范围和预测）

Global Nasal Drug Delivery Technology Market Size By Product Type, By Container, By Application, By End- Users, And By Geographic Scope And Forecast

出版日期: 2024年09月07日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

鼻腔给药技术市场规模及预测

鼻腔给药技术市场规模在 2023 年估计为 769.2 亿美元，预计到 2031 年将达到 1245.4 亿美元，2024 年至 2031 年的复合年增长率为 6.85%。鼻腔给药技术是透过鼻腔给药，使药物直接进入体循环。此技术的优点包括患者依从性好、可透过嗅觉神经将药物直接输送到大脑、方便且能达到血液中的治疗药物水平。

预计未来几年，自我给药的日益普及和慢性病的增加将推动鼻腔给药市场的发展。

预计市场将受益于对替代药物输送方式、技术进步、新产品创新和併购活动的日益增长的偏好，这些预计将在预测期内推动市场成长。

鼻腔给药技术的全球市场动态

主要市场驱动因子

慢性呼吸道疾病发生率不断上升：

全球气喘、慢性阻塞性肺病（COPD）和过敏性鼻炎等疾病的发生率不断上升，对以非侵入性、便捷的方式将药物直接输送到呼吸道的需求正在迅速增加。更快的吸收速度和提高患者依从性的需求推动了鼻腔给药解决方案的使用。

自我治疗需求不断成长：

越来越多的患者为了方便和控制治疗而寻求自我用药的选择。因此，鼻腔给药系统通常易于使用且只需要极少的培训，适合在家中自行使用。

药物配方与输送技术的进步：

技术的进步促进了新型鼻腔给药系统的开发，该系统具有更好的标靶给药、控制释放和增加生物利用度（进入血液的药物百分比）。这些进步正在带来更有效、以患者为中心的治疗选择。

更重视病患的便利性与依从性：

医疗保健产业越来越注重提高病患的便利性和对治疗方案的依从性。在这方面，鼻腔给药具有多种优势，包括非侵入性、易于使用和快速起效。

主要问题

克服解剖学和生理学障碍：

药物的有效传递和分布受到鼻腔复杂解剖结构的影响，包括狭窄的空间、黏液清除机制和有限的吸收表面积。

确保药物传递的稳定性：

酵素和黏液的存在通常有助于药物在鼻腔中的分解。为了应对这些课题，需要仔细考虑药物输送到鼻腔的稳定性和控制释放机制。

病人接受度与易用性：

鼻腔喷雾剂和其他给药装置的易用性至关重要，尤其是对于儿科和老年患者而言。解决不适、剂量准确性和鼻腔刺激等潜在副作用等问题对于患者接受度至关重要。

法规要求和严格测试：

鼻腔给药系统受到监管机构制定的严格指导方针的约束，包括安全性、有效性和品质控制。合规性要求进行大量的临床前和临床测试，这既费时又昂贵。

主要趋势

越来越多的病患选择非侵入式、便利的药物传递方式：

非侵入性、便利的药物传递方法越来越受到病患的需求。鼻腔给药比口服和注射药物等传统方法有几个优点。鼻腔喷雾剂和滴剂通常比药片或註射剂更容易使用，尤其是对于儿童和老年人。此外，与口服药物相比，鼻腔给药的药物可以到达血液并更快地发挥作用。

自我管理的盛行：

自我用药的趋势推动了对使用者友善且方便的鼻腔给药装置的需求。这种趋势对于过敏或偏头痛等慢性病尤其重要，因为患者需要频繁服药。远距医疗和远距病人监测的进步为联网鼻腔给药装置的使用创造了机会。这些设备可以监测药物使用并向医疗保健提供者提供即时数据，增强患者护理管理。

居家医疗保健设备需求不断成长：

慢性病发病率的上升和向家庭医疗保健的日益转变推动了对家庭鼻腔给药设备的需求。这些设备使患者能够在家中接受治疗，从而改善生活品质并降低医疗成本。

Nasal Drug Delivery Technology Market size is estimated at USD 76.92 Billion in 2023 and is projected to reach USD 124.54 Billion by 2031 , growing at a CAGR of 6.85% from 2024 to 2031. Nasal drug delivery technology is a technique utilized for administering drugs through the nasal route, facilitating direct access to systemic circulation. Advantages offered by this technique include good patient compliance, the potential for direct drug delivery to the brain via the olfactory nerves, convenience, and rapid attainment of therapeutic drug levels in the blood.

The Nasal Drug Delivery Technology Market is expected to be driven by the growing adoption of self-administration and increasing incidences of chronic diseases over the predicted years.

The market is anticipated to benefit from the rising preference for an alternative mode of drug administration, technological advancements, new product innovations, and merger & acquisition activities, which are predicted to fuel market growth during the forecasted period.

Global Nasal Drug Delivery Technology Market Dynamics

The key market dynamics that are shaping the Nasal Drug Delivery Technology Market include:

Key Market Drivers

Rising Prevalence of Chronic Respiratory Diseases:

The growing prevalence of conditions like asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis worldwide is surging demand for a non-invasive and convenient way to administer medication directly to the respiratory tract. This need for faster absorption and improved patient compliance is spurring the use of nasal drug delivery solutions.

Growing Demand for Self-Administered Treatments:

Self-administered medication options are increasingly sought by patients for enhanced convenience and control over their treatment. Thus, nasal drug delivery systems are often user-friendly and require minimal training, making them suitable for self-administration at home.

Technological Advancements in Drug Formulation and Delivery:

Advancements in technology are facilitating the development of novel nasal drug delivery systems with improved targeted delivery, controlled release, and enhanced bioavailability (the proportion of a drug that enters the bloodstream). These advancements are leading to the creation of more effective and patient-centric treatment options.

Increasing Focus on Patient Convenience and Compliance:

The healthcare industry is witnessing a growing emphasis on improving patient convenience and compliance with treatment regimens. Nasal drug delivery offers several advantages in this regard, including its non-invasive nature, ease of use, and rapid onset of action.

Key Challenges

Overcoming Anatomical and Physiological Barriers:

The efficient delivery and distribution of drugs is affected by the complex structure of the nasal cavity, which includes narrow spaces, mucus clearance mechanisms, and limited absorption surface area.

Ensuring Drug Stability and Delivery:

Drug degradation in the nasal cavity is often facilitated by enzymes and the presence of mucus. Formulating drugs for nasal delivery requires careful consideration of stability and controlled release mechanisms to address these challenges.

Patient Acceptance and Usability:

User-friendliness of nasal sprays and other delivery devices is particularly crucial, especially for children or elderly patients. Addressing issues such as discomfort, dosing accuracy, and potential side effects like nasal irritation is essential for patient acceptance.

Regulatory Requirements and Stringent Testing:

Strict guidelines for nasal drug delivery systems, encompassing safety, efficacy, and quality control, are imposed by regulatory agencies. Compliance necessitates extensive preclinical and clinical testing, which can be both time-consuming and expensive.

Key Trends

Rising Patient Preference for Non-Invasive and Convenient Drug Delivery:

Non-invasive and convenient drug delivery methods are increasingly sought by patients. Several advantages are offered by nasal drug delivery over traditional methods such as oral or injectable medications. These advantages include: nasal sprays and drops are generally found to be easier to use than pills or injections, particularly for children or elderly patients, drugs administered nasally can reach the bloodstream and take effect more quickly compared to orally administered medications, and nasal delivery bypasses the digestive system, potentially minimizing side effects like nausea or stomach upset.

Growing Adoption of Self-Administration Practices:

The trend toward self-administration of medications is propelling the demand for user-friendly and convenient nasal drug delivery devices. This trend is particularly relevant for chronic conditions such as allergies or migraines, where patients may require frequent medication administration. Opportunities are emerging for the use of connected nasal drug delivery devices due to advancements in telemedicine and remote patient monitoring. These devices can monitor medication usage and furnish real-time data to healthcare providers, enhancing patient care management.

Increasing Demand for Home Healthcare Devices:

The rising prevalence of chronic diseases and the growing shift towards home healthcare are fueling the demand for home-based nasal drug delivery devices. These devices enable patients to receive treatment in their own homes, thereby enhancing their quality of life and reducing healthcare costs.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Nasal Drug Delivery Technology Market Regional Analysis

Here is a more detailed regional analysis of the Nasal Drug Delivery Technology Market:

North America

Novel nasal drug delivery technologies are heavily invested in by North American institutions, leading to market domination.

Approval of new technologies is expedited by favorable regulatory frameworks, such as the FDA's, solidifying North America's dominance.

Nasal drug delivery methods are widely accepted by the public, creating a strong North American market for new products.

Innovation and market growth in the nasal drug delivery sector are fueled by a thriving venture capital ecosystem, further strengthening North America's leading position.

Asia Pacific

Increasing investment in research and development by Asian Pacific institutions drives advancements in nasal drug delivery technology.

Regulatory reforms and streamlined approval processes in the region encourage the adoption of novel nasal drug delivery technologies.

Growing awareness and acceptance of nasal drug delivery methods among the population in the Asia Pacific contribute toward helping it grow at a rapid rate over the forecast period.

Global Nasal Drug Delivery Technology Market: Segmentation Analysis

The Global Nasal Drug Delivery Technology Market is Segmented on the basis of Product Type, Container, Application, End-Users, and Geography.

Nasal Drug Delivery Technology Market, By Product Type

Sprays
Drops
Gels
Powders
Inhalers

Based on Product Type, the market is segmented into Sprays, Drops, Gels, Powders, and Inhalers. The highest market share in the Nasal Drug Delivery Technology Market is held by nasal sprays. Nasal sprays are favored due to their ease of administration, rapid onset of action, and suitability for delivering a wide range of medications, making them the preferred choice for both patients and healthcare providers. Their dominant position in the market is significantly contributed to by their versatility and effectiveness.

Nasal Drug Delivery Technology Market, By Application

Allergic Rhinitis
Congestion
Infections
Vaccination
Opioid Overdose Reversal
Others

Based on Application, the market is segmented into Allergic Rhinitis, Congestion, Infections, Vaccination, Opioid Overdose Reversal, and Others. The Nasal Drug Delivery Technology Market is dominated by Allergic Rhinitis. It is prevalent worldwide and drives the demand for nasal drug delivery systems due to the frequent need for medication administration. Nasal sprays are commonly utilized to alleviate allergic rhinitis symptoms because of their rapid onset of action and targeted delivery to the nasal mucosa.

Nasal Drug Delivery Technology Market, By End-Users

Hospitals
Clinics
Ambulatory Surgical Centers
Homecare Settings
Others

Based on End-Users, the market is segmented into Hospitals, Clinics, Ambulatory Surgical Centers, Homecare Settings, and Others. Homecare Settings dominate the Nasal Drug Delivery Technology Market. This dominance is attributed to the rising trend of self-administration and the convenience of using nasal drug delivery systems at home. Advancements in technology have enabled the development of user-friendly devices suitable for home use, further driving the demand in this segment.

Nasal Drug Delivery Technology Market, By Container

Non-Pressurized
Pressurized

Based on Container, the market is segmented into Non-Pressurized and Pressurized containers. Non-pressurized segment is anticipated to dominate the market over the forecast period. Growing concerns about environmental impact and potential health risks associated with propellants is surging demand for alternative delivery methods such as pumps or atomizer mechanisms.

Key Players

The "Nasal Drug Delivery Technology Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as
Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Johnson & Johnson Services Inc., Pfizer Inc., AstraZeneca PLC, AptarGroup Inc., Aegis Therapeutics LLC, 3M, Becton, Dickinson, and Company.

Our market analysis includes a section specifically devoted to such major players, where our analysts give an overview of each player's financial statements, along with product benchmarking and SWOT analysis. Key development strategies, market share analysis, and market positioning analysis of the aforementioned players globally are also included in the competitive landscape section.

Nasal Drug Delivery Technology Market Recent Developments
In October 2023, the launch of its Unidose+ nasal spray platform was announced by Aptar Pharma, a leading provider of drug delivery systems, specifically designed for high-viscosity and challenging-to-formulate drugs.
In September 2023, a collaboration agreement was entered into by Vectura Group, a pharmaceutical company specializing in inhalation and nasal drug delivery, with ALX Oncology to develop and commercialize a novel nasal spray formulation of ALX148 for the treatment of head and neck cancers.
In August 2023, the approval of AstraZeneca's RINVOQ nasal spray by the U.S. Food and Drug Administration (FDA) was announced, making it the first IL-12/23 inhibitor approved for the treatment of moderate-to-severe chronic rhinosinusitis with nasal polyps.

1 INTRODUCTION OF GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY CONTAINER

5.1 Overview
5.2 Non-Pressurized
5.3 Pressurized

6 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY PRODUCT TYPE

6.1 Overview
6.2 Sprays
6.3 Drops
6.4 Gels
6.5 Powders
6.6 Inhalers

7 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY END-USERS

7.1 Overview
7.2 Hospitals
7.3 Clinics
7.4 Ambulatory Surgical Centers
7.5 Homecare Settings
7.6 Others

8 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY THERAPEUTIC APPLICATION

8.1 Overview
8.2 Allergic Rhinitis
8.3 Congestion
8.4 Infections
8.5 Vaccination
8.6 Opioid Overdose Reversal
8.7 Others

9 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Rest of the World
- 9.5.1 Latin America
- 9.5.2 Middle East and Africa

10 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Share
10.3 Vendor Landscape
10.4 Key Development Strategies

11 COMPANY PROFILES

11.1 Merck & Co., Inc.
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 Novartis AG
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 Glaxosmithkline PLC
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 Johnson & Johnson Services, Inc.
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 Pfizer Inc.
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 Astrazeneca PLC
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Developments
11.7 Aptargroup, Inc.
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 Aegis Therapeutics LLC
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11.9 3M
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Developments
11.10 Becton Dickinson and Company
- 11.10.1 Overview
- 11.10.2 Financial Performance
- 11.10.3 Product Outlook
- 11.10.4 Key Developments